Secukinumab (AIN-457) for the treatment of Psoriasis.
Publication
, Journal Article
Jaleel, T; Elmets, C; Weinkle, A; Kassira, S; Elewski, B
Published in: Expert Rev Clin Pharmacol
2016
Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review will address the rationale for targeting the IL-23/Th17/IL-17 axis, the role of IL-17 and Th17 cells in psoriasis and other chronic inflammatory diseases, and will examine pre-clinical studies, pharmacologic properties, clinical efficacy, and the safety profile of secukinumab.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Expert Rev Clin Pharmacol
DOI
EISSN
1751-2441
Publication Date
2016
Volume
9
Issue
2
Start / End Page
187 / 202
Location
England
Related Subject Headings
- Severity of Illness Index
- Psoriasis
- Pharmacology & Pharmacy
- Interleukin-17
- Humans
- Dermatologic Agents
- Arthritis, Psoriatic
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Animals
Citation
APA
Chicago
ICMJE
MLA
NLM
Jaleel, T., Elmets, C., Weinkle, A., Kassira, S., & Elewski, B. (2016). Secukinumab (AIN-457) for the treatment of Psoriasis. Expert Rev Clin Pharmacol, 9(2), 187–202. https://doi.org/10.1586/17512433.2016.1129894
Jaleel, Tarannum, Craig Elmets, Allison Weinkle, Sama Kassira, and Boni Elewski. “Secukinumab (AIN-457) for the treatment of Psoriasis.” Expert Rev Clin Pharmacol 9, no. 2 (2016): 187–202. https://doi.org/10.1586/17512433.2016.1129894.
Jaleel T, Elmets C, Weinkle A, Kassira S, Elewski B. Secukinumab (AIN-457) for the treatment of Psoriasis. Expert Rev Clin Pharmacol. 2016;9(2):187–202.
Jaleel, Tarannum, et al. “Secukinumab (AIN-457) for the treatment of Psoriasis.” Expert Rev Clin Pharmacol, vol. 9, no. 2, 2016, pp. 187–202. Pubmed, doi:10.1586/17512433.2016.1129894.
Jaleel T, Elmets C, Weinkle A, Kassira S, Elewski B. Secukinumab (AIN-457) for the treatment of Psoriasis. Expert Rev Clin Pharmacol. 2016;9(2):187–202.
Published In
Expert Rev Clin Pharmacol
DOI
EISSN
1751-2441
Publication Date
2016
Volume
9
Issue
2
Start / End Page
187 / 202
Location
England
Related Subject Headings
- Severity of Illness Index
- Psoriasis
- Pharmacology & Pharmacy
- Interleukin-17
- Humans
- Dermatologic Agents
- Arthritis, Psoriatic
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Animals